RxDoctor Payments Data

Lauren Ledoux

Family · Lafayette, LANPI 1225583842

Payments from drug & device makers

$2,851in general payments, 2019–2025

Across 180 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$504
  • Amgen$383
  • AstraZeneca$310
  • Novo Nordisk$272
  • Lilly USA, LLC$212
  • Takeda Pharmaceuticals U.S.A., Inc.$143
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,80298%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,851 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$80,393
Medicare patients
419
Services billed
1,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol15$15,583
OzempicSemaglutide15$13,100
JardianceEmpagliflozin17$11,873
JanuviaSitagliptin Phosphate11$5,818
Ibandronate Sodium16$762
Atorvastatin Calcium25$335
Gabapentin18$240
Methylprednisolone45$237
Escitalopram Oxalate18$194
Pantoprazole Sodium18$187
Amlodipine Besylate23$177
Lisinopril16$175
Levothyroxine Sodium25$156
Rosuvastatin Calcium24$133
Sertraline Hcl11$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$310$15,58315 claims
Novo NordiskOzempic$272$13,10015 claims
Boehringer IngelheimJardiance$100$11,87317 claims
MerckJanuvia$11$5,81811 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$15625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →